vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and ENNIS, INC. (EBF). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $100.2M, roughly 1.8× ENNIS, INC.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 10.8%, a 2.5% gap on every dollar of revenue. On growth, ENNIS, INC. posted the faster year-over-year revenue change (0.4% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $15.7M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs 1.4%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
ENNIS, INC. (ticker EBF) is a leading North American provider of printed business products and related services. Its offerings include custom business forms, pressure-sensitive labels, marketing collateral, promotional items, and branded packaging, serving clients across retail, healthcare, financial services, and small business segments.
AMPH vs EBF — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $100.2M |
| Net Profit | $24.4M | $10.8M |
| Gross Margin | 46.8% | 31.9% |
| Operating Margin | 19.4% | 15.0% |
| Net Margin | 13.3% | 10.8% |
| Revenue YoY | -1.8% | 0.4% |
| Net Profit YoY | -35.7% | 6.1% |
| EPS (diluted) | $0.51 | $0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $100.2M | ||
| Q3 25 | $191.8M | $98.7M | ||
| Q2 25 | $174.4M | $97.2M | ||
| Q1 25 | $170.5M | $92.7M | ||
| Q4 24 | $186.5M | $99.8M | ||
| Q3 24 | $191.2M | $99.0M | ||
| Q2 24 | $182.4M | $103.1M | ||
| Q1 24 | $171.8M | $97.4M |
| Q4 25 | $24.4M | $10.8M | ||
| Q3 25 | $17.4M | $13.2M | ||
| Q2 25 | $31.0M | $9.8M | ||
| Q1 25 | $25.3M | $9.0M | ||
| Q4 24 | $38.0M | $10.2M | ||
| Q3 24 | $40.4M | $10.3M | ||
| Q2 24 | $37.9M | $10.7M | ||
| Q1 24 | $43.2M | $10.1M |
| Q4 25 | 46.8% | 31.9% | ||
| Q3 25 | 51.4% | 30.5% | ||
| Q2 25 | 49.6% | 31.1% | ||
| Q1 25 | 50.0% | 29.5% | ||
| Q4 24 | 46.5% | 29.3% | ||
| Q3 24 | 53.3% | 30.1% | ||
| Q2 24 | 52.2% | 30.0% | ||
| Q1 24 | 52.4% | 28.4% |
| Q4 25 | 19.4% | 15.0% | ||
| Q3 25 | 13.2% | 12.5% | ||
| Q2 25 | 24.2% | 13.7% | ||
| Q1 25 | 21.9% | 13.0% | ||
| Q4 24 | 24.2% | 13.1% | ||
| Q3 24 | 29.8% | 13.3% | ||
| Q2 24 | 30.3% | 13.3% | ||
| Q1 24 | 27.9% | 13.3% |
| Q4 25 | 13.3% | 10.8% | ||
| Q3 25 | 9.0% | 13.3% | ||
| Q2 25 | 17.8% | 10.1% | ||
| Q1 25 | 14.8% | 9.7% | ||
| Q4 24 | 20.4% | 10.2% | ||
| Q3 24 | 21.1% | 10.4% | ||
| Q2 24 | 20.8% | 10.4% | ||
| Q1 24 | 25.1% | 10.4% |
| Q4 25 | $0.51 | $0.42 | ||
| Q3 25 | $0.37 | $0.51 | ||
| Q2 25 | $0.64 | $0.38 | ||
| Q1 25 | $0.51 | $0.34 | ||
| Q4 24 | $0.74 | $0.39 | ||
| Q3 24 | $0.78 | $0.40 | ||
| Q2 24 | $0.73 | $0.41 | ||
| Q1 24 | $0.81 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $31.3M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $304.8M |
| Total Assets | $1.6B | $354.3M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $31.3M | ||
| Q3 25 | $276.2M | $31.9M | ||
| Q2 25 | $231.8M | $32.6M | ||
| Q1 25 | $236.9M | $72.5M | ||
| Q4 24 | $221.6M | $68.6M | ||
| Q3 24 | $250.5M | $122.6M | ||
| Q2 24 | $217.8M | $123.7M | ||
| Q1 24 | $289.6M | $110.9M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $304.8M | ||
| Q3 25 | $776.7M | $305.4M | ||
| Q2 25 | $757.5M | $301.2M | ||
| Q1 25 | $751.3M | $302.0M | ||
| Q4 24 | $732.3M | $297.7M | ||
| Q3 24 | $727.7M | $358.4M | ||
| Q2 24 | $713.3M | $354.4M | ||
| Q1 24 | $672.4M | $349.8M |
| Q4 25 | $1.6B | $354.3M | ||
| Q3 25 | $1.7B | $361.8M | ||
| Q2 25 | $1.6B | $361.7M | ||
| Q1 25 | $1.6B | $348.9M | ||
| Q4 24 | $1.6B | $346.1M | ||
| Q3 24 | $1.5B | $406.8M | ||
| Q2 24 | $1.5B | $406.2M | ||
| Q1 24 | $1.6B | $399.2M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $16.4M |
| Free Cash FlowOCF − Capex | $24.6M | $15.7M |
| FCF MarginFCF / Revenue | 13.4% | 15.7% |
| Capex IntensityCapex / Revenue | 4.5% | 0.7% |
| Cash ConversionOCF / Net Profit | 1.35× | 1.52× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $42.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $16.4M | ||
| Q3 25 | $52.6M | $10.5M | ||
| Q2 25 | $35.6M | $8.0M | ||
| Q1 25 | $35.1M | $12.8M | ||
| Q4 24 | $29.0M | $18.2M | ||
| Q3 24 | $60.0M | $11.8M | ||
| Q2 24 | $69.1M | $23.1M | ||
| Q1 24 | $55.3M | $16.6M |
| Q4 25 | $24.6M | $15.7M | ||
| Q3 25 | $47.2M | $9.0M | ||
| Q2 25 | $25.0M | $6.6M | ||
| Q1 25 | $24.4M | $11.1M | ||
| Q4 24 | $16.6M | $17.5M | ||
| Q3 24 | $46.2M | $10.7M | ||
| Q2 24 | $63.1M | $20.6M | ||
| Q1 24 | $46.5M | $15.0M |
| Q4 25 | 13.4% | 15.7% | ||
| Q3 25 | 24.6% | 9.2% | ||
| Q2 25 | 14.3% | 6.8% | ||
| Q1 25 | 14.3% | 12.0% | ||
| Q4 24 | 8.9% | 17.6% | ||
| Q3 24 | 24.1% | 10.8% | ||
| Q2 24 | 34.6% | 20.0% | ||
| Q1 24 | 27.1% | 15.3% |
| Q4 25 | 4.5% | 0.7% | ||
| Q3 25 | 2.8% | 1.4% | ||
| Q2 25 | 6.1% | 1.4% | ||
| Q1 25 | 6.3% | 1.8% | ||
| Q4 24 | 6.7% | 0.6% | ||
| Q3 24 | 7.2% | 1.1% | ||
| Q2 24 | 3.3% | 2.4% | ||
| Q1 24 | 5.1% | 1.7% |
| Q4 25 | 1.35× | 1.52× | ||
| Q3 25 | 3.03× | 0.80× | ||
| Q2 25 | 1.15× | 0.81× | ||
| Q1 25 | 1.39× | 1.41× | ||
| Q4 24 | 0.76× | 1.78× | ||
| Q3 24 | 1.48× | 1.15× | ||
| Q2 24 | 1.82× | 2.16× | ||
| Q1 24 | 1.28× | 1.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
EBF
Segment breakdown not available.
